EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Lost and found in translation: the value of the human imiquimod model

Anouk C Meijs iD, Juliette A van den Noort iD, Salma Assil, Naomi B Klarenbeek, Matthijs Moerland, Tessa Niemeyer-van der Kolk iD, Robert Rissmann iD

British Journal of Clinical Pharmacology · 2026-06-12

DOI: 10.1002/bcp.70643 ↗

At a glance

Journal article in British Journal of Clinical Pharmacology, published online on 2026-06-12. Written by Anouk C Meijs and 6 co-authors. Institution: Centre for Human Drug Research, Leiden, The Netherlands. 28 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis. To bridge this translational gap, we compare here the experimental conduct, readouts and mechanistic insights engaged by IMQ challenge in mice vs . healthy human participants. Importantly, molecular and cellular analyses indicate that IMQ predominantly activates interferon regulatory factor (IRF) signalling in humans, rather than NF‐κB pathways as observed in animals. Moreover, differences in neutrophil response and complement activation were also identified. These discrepancies may reflect interspecies variation in TLR7 expression as well as methodological differences between the animal and human IMQ model. Despite certain limitations related to psoriasis translatability, the human IMQ model has demonstrated translational relevance in several early phase clinical trials. It represents a valuable tool for evaluating target engagement and characterizing downstream pharmacodynamic effects of novel compounds, particularly those targeting the TLR7–IRF‐type I interferon axis. In conclusion, the human IMQ model can serve as valuable mechanistic model driving disease‐related pathways, rather than as a proxy for plaque psoriasis disease biology. Fit‐for‐purpose benchmarking and method standardization are essential to maximize translational utility of the IMQ model.

Subjects

Author keywords

animal modelsimmunosuppressioninflammationphase Itranslational research

Authors and institutions

  • Centre for Human Drug Research, Leiden, The Netherlands.
  • Leiden University Medical Center, Leiden, The Netherlands.
  • Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
  • Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.

ORCID profiles: Anouk C Meijs, Juliette A van den Noort, Tessa Niemeyer-van der Kolk, Robert Rissmann

Cite

APA

Meijs, A. C., van den Noort, J. A., Assil, S., Klarenbeek, N. B., Moerland, M., Niemeyer-van der Kolk, T., & Rissmann, R. (2026). Lost and found in translation: the value of the human imiquimod model. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70643

Vancouver

Meijs AC, van den Noort JA, Assil S, Klarenbeek NB, Moerland M, Niemeyer-van der Kolk T, et al. Lost and found in translation: the value of the human imiquimod model. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70643

BibTeX
@article{Meijs2026,
  author = {Meijs, Anouk C and van den Noort, Juliette A and Assil, Salma and Klarenbeek, Naomi B and Moerland, Matthijs and Niemeyer-van der Kolk, Tessa and Rissmann, Robert},
  title = {Lost and found in translation: the value of the human imiquimod model},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70643}
}
Start for free →